| Cover | Jan. 13, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jan. 13, 2022 |
| Entity File Number | 001-39069 |
| Entity Registrant Name | Aprea Therapeutics, Inc. |
| Entity Central Index Key | 0001781983 |
| Entity Tax Identification Number | 84-2246769 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 535 Boylston Street |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02116 |
| City Area Code | 617 |
| Local Phone Number | 463-9385 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, par value $0.001 per share |
| Trading Symbol | APRE |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | true |
